1. INTRODUCTION
===============

Surgery has traditionally been considered the standard therapy for localized esophageal cancer [@b1-co16-4-48]. Post-operative radiation therapy ([rt]{.smallcaps}) [@b2-co16-4-48],[@b3-co16-4-48] and postoperative chemoradiation [@b4-co16-4-48]--[@b6-co16-4-48] have been used for esophageal cancer patients deemed to be at high risk for recurrence after esophagectomy. As compared with surgery alone, postoperative chemotherapy and [rt]{.smallcaps} [@b7-co16-4-48],[@b8-co16-4-48] have been reported to be beneficial with regard to survival.

Optimal [rt]{.smallcaps} target-volume definition in esophageal cancer patients receiving primary chemoradiation is controversial [@b9-co16-4-48], partly because of the significant changes in patient anatomy and function, and partly because of the limited information available to evaluate the benefit on anastomotic site coverage in the postsurgical [rt]{.smallcaps} target volume. The literature contains limited retrospective or prospective information regarding the necessity for irradiation of the anastomosis and regarding the safety of the relatively large treatment volume when combined with chemotherapy postoperatively. We previously reported a retrospective analysis of extended-volume external-beam [rt]{.smallcaps} with a clinical target volume ([ctv]{.smallcaps}) covering the anastomotic site in post-esophagectomy high-risk patients [@b10-co16-4-48]. The present study was our local prospective pilot trial assessing the feasibility of incorporating the extended-volume regimen into [rt]{.smallcaps} planning for a postsurgical adjuvant trial in esophageal cancer.

2. PATIENTS AND METHODS
=======================

From 2001 to 2006, we prospectively accrued 15 patients with resected esophageal cancer to this pilot study at the London Regional Cancer Program to evaluate the adverse effects of postoperative extended-volume [rt]{.smallcaps} delivered with concurrent chemotherapy and of the complications of extended-volume [rt]{.smallcaps} concurrent with chemotherapy. Eligibility criteria were pathology-proven esophageal malignancy; 2002 American Joint Committee on Cancer [@b11-co16-4-48] stage T3--4, N0--1 disease; and esophagectomy with or without resection margin involvement. Patients with distant metastasis (M1), those who had received previous [rt]{.smallcaps}, or those who declined to sign a consent form were excluded.

Adjuvant therapy consisted of chemotherapy followed by concurrent chemoradiation 4 weeks post surgery or as soon as the patient recovered from the surgical procedure. Chemotherapy consisted of 4 cycles of epirubicin 50 mg/m^2^ day 1, 5-fluorouracil 200 mg/m^2^ continuous infusion for 21 days, and cisplatin 60 mg/m^2^ day 1, repeated every 21 days, with epirubicin omitted during the concurrent phase with [rt]{.smallcaps}.

Delivery of the external-beam [rt]{.smallcaps} used conformal computed tomography ([ct]{.smallcaps}) planning, with a multi-field arrangement tailored to the pathology findings and a [ctv]{.smallcaps} encompassing the primary tumour bed and the anastomotic site in the neck. The initial [rt]{.smallcaps} target volume was defined with margins of 5 cm above and below the presurgical gross tumour volume, and a 2-cm margin to cover the mediastinal lymph nodes medially and laterally, with the superior margin extended at least 2 cm above the anastomotic site [@b10-co16-4-48] ([Figure 1](#f1-co16-4-48){ref-type="fig"}). The boost fields had minimum 2-cm margins around the presurgical target volume. The total [rt]{.smallcaps} dose was 50.4 Gy, with 1.8 Gy per fraction (initially 30.6 Gy in 17 fractions, followed by 19.8 Gy in 11 fractions), delivered concurrently with the third cycle of chemotherapy.

Follow-up evaluations of the patients were performed every 3 months during years 1--2, every 4 months during years 3--4, every 6 months during year 5, and annually thereafter. Follow-up investigations included screening blood cell count and chemistries, chest radiography, and [ct]{.smallcaps} of chest and abdomen. At the time of relapse, investigations were carried out as clinically indicated and included endoscopy; barium-swallow esophagram; brain, chest, and abdominal [ct]{.smallcaps}; and bone scan.

Local relapse was defined as tumour recurrence at or immediately adjacent to the anastomotic site. Regional relapse was defined as recurrence at the mediastinum or peri-esophageal region (or both), excluding local relapse. Distant relapse was tumour recurrence at distant site---for example, brain, liver, or lung.

Treatment--related toxicities were assessed using the U.S. National Cancer Institute ([nci]{.smallcaps} ) Common Toxicity Criteria. Acute (90 or fewer days from [rt]{.smallcaps} start) side effects of radiation therapy were documented using the revised [nci]{.smallcaps} Common Toxicity Criteria [@b12-co16-4-48].

Grade 2 esophagitis related to [rt]{.smallcaps} was described as dysphagia, requiring predominantly pureed, soft, or liquid diet for acute effect; inability to take solid food normally; swallowing semisolid food; and need for dilation for late effect. Late [rt]{.smallcaps} toxicity is defined as an adverse event occurring more than 90 days from [rt]{.smallcaps} start, according to the Late Radiation Morbidity Scoring Scheme from the Radiation Therapy Oncology Group ([rtog]{.smallcaps}) and the European Organization for Research and Treatment of Cancer, and the [nci]{.smallcaps} 1999 Common Toxicity Criteria. Late gastrointestinal [rt]{.smallcaps} morbidity ([rtog]{.smallcaps} grading system)---grade 2 toxicity described as moderate diarrhea and colic with bowel movement more than 5 times daily, or intermittent bleeding---was also analyzed.

For the purpose of the study, the marker for any toxicity-related treatment break was measured by the length (in days) of the interruption in the chemotherapy or [rt]{.smallcaps} schedule arising during the concurrent phase of chemoradiation treatment. Hematologic criteria for interruptions during concurrent chemotherapy [rt]{.smallcaps} included absolute neutrophil count below 1000/mm^3^; neutropenic fever or sepsis; thrombocytes below 80,000/mm^3^. Locoregional symptomatology for treatment interruption included severe esophagitis (that is, severe odynophagia or dysphagia, intolerable pain), impaired nutrition with nausea and vomiting; and dehydration requiring hospitalization [@b10-co16-4-48].

Overall survival ([os]{.smallcaps}) was defined as the interval between the date of pathology diagnosis and death or last follow-up, with any death being defined as an event. Disease-free survival ([dfs]{.smallcaps}) was defined as the interval between the date of pathology diagnosis and the date of first recurrence or last follow-up, with recurrence treated as an event. Survival estimates were obtained using the Kaplan--Meier method [@b13-co16-4-48].

3. RESULTS
==========

[Table I](#tI-co16-4-48){ref-type="table"} summarizes the characteristics of the study cohort. The 15 subjects (10 men, 5 women) had a median age of 64 years (range: 48--80 years). The TNM stages in the group were T3N0 (*n* = 1), T2N1 (*n* = 2), T3N1 (*n* = 11), and T4N1 (*n* = 1). Histopathology included 5 adenocarcinomas and 10 squamous-cell carcinomas. Surgery was either transhiatal (87%) or transthoracic (13%), with clear resection margins in 10 patients and a close or positive radial resection margin in 5 ([Table I](#tI-co16-4-48){ref-type="table"}). The median follow-up was 19 months (range: 3.5--53.4 months).

[Table II](#tII-co16-4-48){ref-type="table"} summarizes the treatment characteristics in the patient cohort. Before the start of [rt]{.smallcaps}, delay in chemotherapy and chemotherapy dose reduction occurred in 20% and 13.3% of the patients respectively. During concurrent chemoradiation, these proportions were 20% and 6.6%.

These reasons were cited for chemotherapy delay:

-   Cycle 1: physician and patient choice

-   Cycle 2: febrile neutropenia, diarrhea

-   Cycle 3 (with [rt]{.smallcaps}): neutropenia

-   Cycle 4 (with [rt]{.smallcaps}): neutropenia and patient choice

These reasons were cited for chemotherapy dose reduction:

-   Cycle 1: no dose reductions

-   Cycle 2: febrile neutropenia, diarrhea, and physician choice

-   Cycle 3 (with [rt]{.smallcaps}): febrile neutropenia, mucositis, hand--foot syndrome

-   Cycle 4 (with [rt]{.smallcaps}): patient choice

No [rt]{.smallcaps} delays or [rt]{.smallcaps} dose reductions occurred in this patient cohort.

During the concurrent chemoradiation treatment period, 1 patient experienced grade 1 esophagitis, and 1 patient, grade 2 nausea and vomiting. The constitutional symptoms observed were moderate taste alteration in 2 patients and poor appetite in 3 patients.

During the follow-up period 90 or fewer days from [rt]{.smallcaps} start, 2 patients had grade 1 cough, 1 patient had grade 1 nausea and vomiting, 1 patient had grade 1 esophagitis, 1 patient had grade 2 nausea and vomiting, and 1 patient had grade 2 diarrhea and abdominal cramps. The constitutional symptoms observed were mild-to-moderate taste alteration in 2 patients and mild poor appetite and low energy level in 3 patients.

During the follow-up period more than 90 days from [rt]{.smallcaps} start, 2 patients had grade 1 shortness of breath; 1 patient had grade 2 pneumonitis; 2 patients had grade 2 dysphagia, difficulty with solid food requiring esophagoscopy and dilatation for anastomotic strictures; and 2 patients had grade 1 nausea and vomiting. The constitutional symptoms observed were grade 1 fatigue (increase in fatigue over baseline, but not altering normal activities) in 2 patients, moderate taste alteration in 1 patient, and mild poor appetite in 1 patient ([Table III](#tIII-co16-4-48){ref-type="table"}).

No treatment-related esophagitis or pneumonitis of greater than grade 2 was observed during treatment and in the follow-up assessments. No chemoradiation treatment--related mortality occurred in the study cohort: specifically, no anastomotic leaks or wound breakdown occurred.

Disease recurrence was observed in 40% (6/15) of the patients, with median time to relapse being 24 months ([Figure 2](#f2-co16-4-48){ref-type="fig"}). No tumour recurrence at the anastomotic site was observed. Relapses were exclusively distant metastases, with lung and liver as the most common sites ([Table IV](#tIV-co16-4-48){ref-type="table"}). The median, 1-year, and 2-year [dfs]{.smallcaps} and [os]{.smallcaps} rates were 23 months, 80%, and 44% and 21 months, 65%, and 38% respectively.

4. DISCUSSION
=============

The results of this pilot study are consistent with a previous retrospective analysis from our institution reporting complications of extended-volume [rt]{.smallcaps} [@b10-co16-4-48]. The current prospective trial confirmed the absence of grades 3 and 4 adverse effects with the use of extended volume [rt]{.smallcaps} concurrent with chemotherapy. Qiao and co-workers [@b14-co16-4-48] reviewed 102 cases of squamous cell carcinoma of the esophagus receiving postoperative [rt]{.smallcaps} of 50 Gy, in which 43 patients treated with extended [rt]{.smallcaps} fields covering supraclavicular nodes, anastomotic sites, and loco--tumour bed were compared with 59 patients receiving [rt]{.smallcaps} to the loco--tumour bed only. Although [os]{.smallcaps} differences between the two groups were nonsignificant, treatment side effects and complications were also nonsignificantly different (18.6% vs. 11.9%, *p* = 0.343), including no difference in the degree of severity of nausea and anorexia between the two groups. No anastomotic leakage, fistulae, or local disease recurrence were observed during follow-up.

Benign anastomotic stricture can occur as early as 27 days and up to 11 months (median: 2--3 months) post transhiatal esophagectomy in esophageal cancer. Depending on the surgical technique, the anastomotic stricture rate from some surgical series can be as high as 42% [@b15-co16-4-48]--[@b17-co16-4-48]. Singh and co-workers [@b17-co16-4-48] reported that patients who underwent total mechanical anastomosis experienced anastomotic stricture requiring dilation at a rate of 18%. Our current prospective study found a rate of 13% (2 patients) of anastomotic stricture post esophagectomy while receiving adjuvant chemoradiation.

Although the median follow-up in our patient cohort is 19 months at the time of writing, any additional adverse effects from the development of anastomotic stricture while receiving adjuvant chemoradiation have yet to occur. Distinct from the finding in our previous retrospective study of 15% locoregional relapse with a median follow-up of 30 months after extended-volume [rt]{.smallcaps}, the current pilot study, with a shorter median follow-up (19 months), has yet to identify any locoregional recurrence. In the current study, the recurrences (40%) were all in distant sites, with liver and lung being the most common sites. That result is consistent with our previous report that 85% of relapses in patients treated with extended-volume [rt]{.smallcaps} are distant failures.

Although some surgical series have reported that anastomotic recurrence rates are as low as under 5% [@b18-co16-4-48],[@b19-co16-4-48], autopsy studies of patients with advanced tumours have reported tumour at the anastomosis in almost 30% of cases [@b20-co16-4-48]. Consistent with those studies, our previous series reported a 29% anastomotic recurrence rate for high-risk patients in whom the [rt]{.smallcaps} volume did not include the anastomotic site.

Xiao *et al.* [@b21-co16-4-48] reported a series of 549 cases of squamous cell carcinoma of the esophagus. Postoperative [rt]{.smallcaps} with 50--60 Gy significantly reduced the incidence of intrathoracic recurrence in high-risk patients with positive nodes and also in patients with negative nodes. Our current data are consistent with our previous series and similar to data reported by Xiao *et al.* [@b21-co16-4-48], finding that high-risk patients treated with [rt]{.smallcaps} encompassing the anastomosis have not experienced anastomotic site recurrence and that postoperative [rt]{.smallcaps} reduces the risk of intrathoracic recurrence.

The optimal dose for postoperative [rt]{.smallcaps} in esophageal cancer is also controversial. Much of the information on [rt]{.smallcaps} dose has been derived from reports of preoperative management, with a prescribed [rt]{.smallcaps} dose of 30 Gy to the regional nodes and a boost of 20 Gy to the primary tumour, delivered with chemotherapy. This regimen is superior to 64 Gy of [rt]{.smallcaps} alone without chemotherapy [@b22-co16-4-48]. Regimens using a higher [rt]{.smallcaps} dose level of 64.8 Gy have been reported not to be superior to 50.4 Gy concurrently with chemotherapy [@b23-co16-4-48]. In a single-institution study, Yu *et al.* [@b10-co16-4-48] reported that a postoperative [rt]{.smallcaps} dose of 30.6 Gy to anastomotic site and 50.4 Gy to the tumour bed concurrent with chemotherapy is sufficient and significantly reduces recurrence at both the anastomotic site and the tumour bed. Besides esophageal cancer, the management of anal canal cancer [@b24-co16-4-48] has been successful using a [rt]{.smallcaps} dose of 30--36 Gy concurrent with chemotherapy for microscopic disease eradication. That report concurs with Byfield [@b25-co16-4-48] that chemotherapy can enhance the local effects of radiation to reduce the likelihood of spread from the primary, but also to reduce or limit micrometastasis. The [rt]{.smallcaps} dose level sufficient to reduce relapse when delivered to the tumour bed concurrently with chemotherapy, while still balancing acceptable toxicity, is not yet clear. Total [rt]{.smallcaps} doses of 45--50 Gy to the tumour bed have been reported [@b7-co16-4-48],[@b8-co16-4-48],[@b26-co16-4-48] to be acceptable and are associated with tolerable treatment side effects.

We acknowledge several limitations of the present study, including a small sample size and short follow-up. We also acknowledge the relative rarity of the patient group receiving postoperative chemoradiation for high risk of recurrence when preoperative chemoradiation is recommended as the treatment of choice in many cancer treatment centers [@b27-co16-4-48]. However, the findings on treatment toxicity with the use of extended-volume [rt]{.smallcaps} encompassing the anastomotic site postoperatively in high-risk cancer patients in the present prospective study confirm our centre's previously reported retrospective experience that no addition treatment complications---including treatment interruptions and gastrointestinal toxicity--- occur with the use of extended-volume [rt]{.smallcaps} [@b10-co16-4-48].

The management of esophageal carcinoma, particularly with esophageal [rt]{.smallcaps}, has advanced since the end of the 1990s. A single treatment modality for patients with locoregional disease has now been demonstrated to be suboptimal [@b28-co16-4-48],[@b29-co16-4-48]. Tri-modality treatment offers the potential to improve outcomes for patients with high-risk disease. In employing tri-modality therapy, the controversy with respective to whether surgery should be performed before or after chemoradiotherapy remains a topic of debate. The current study demonstrating the safety and feasibility of extended-volume [rt]{.smallcaps} and the associated encouraging early results in locoregional control suggest that this [rt]{.smallcaps} regimen may be incorporated into future studies comparing neoadjuvant chemoradiotherapy with adjuvant chemoradiotherapy trimodality management.

5. CONCLUSIONS
==============

Extended-volume external-beam [rt]{.smallcaps} encompassing the tumour bed and anastomotic site is feasible and safe for high-risk T3--4, N0--1 esophageal cancer patients post esophagectomy.

Part of the content of this paper was presented at the Canadian Association of Radiation Oncology Annual Scientific Meeting, October 11--14, 2007, Toronto, Ontario.
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###### 

Patient demographics

  ------------------ --------
  Age (years)        
   Median            64
   Range             48--80
  Sex                
   Male              10
   Female            5
  Stage              
   T3N0              1
   T2N1              2
   T3N1              11
   T4N1              1
  Tumour pathology   
   Squamous-cell     10
   Adenocarcinoma    5
  Margin status      
   Clear             10
   Close/positive    5
  ------------------ --------

###### 

Chemotherapy delay and dose reduction ([dr]{.smallcaps}) in the study patients

  *Patient [id]{.smallcaps}*   *Chemotherapy cycle*                                  
  ---------------------------- ---------------------- --- ---- ------ ---- ---- ---- -----
  1                            −                      −   −    −      −    −    −    −
  2                            −                      −   −    −      \+   −    \+   \+
  3                            −                      −   −    −      −    −    −    −
  4                            −                      −   −    −      \+   −    \+   −
  5                            −                      −   −    −      −    \+   −    −
  6                            \+                     −   −    \+     −    −    −    −
  7                            −                      −   \+   −      −    \+   −    −
  8                            −                      −   −    −      −    −    −    −
  9                            −                      −   \+   \+     −    −    \+   −
  10                           −                      −   \+   −      \+   −    −    −
  11                           −                      −   −    −      −    \+   −    −
  12                           −                      −   −    −      −    −    −    −
  13                           −                      −   −    −      −    −    −    −
  14                           −                      −   −    −      −    −    −    −
  15                           −                      −   −    −      −    −    −    −
  Overall (%)                  6.6                    0   20   13.3   20   20   20   6.6

[id]{.smallcaps} = identification number; [rt]{.smallcaps}= radiotherapy.

###### 

Side effects and complications in the study patients

  *Adverse events*                                                               *Days from radiotherapy start*                                          
  ------------------------------------------------------------------------------ -------------------------------- -------- --- --- -------- -------- --- ---
  Lung[c](#tfn4-co16-4-48){ref-type="table-fn"} \[*n* (%)\]                      2 (13)                           0        0   0   2 (13)   1 (7)    0   0
  Small/large bowel[d](#tfn5-co16-4-48){ref-type="table-fn"} \[*n* (%)\]         1 (7)                            2 (13)   0   0   2 (13)   0        0   0
  Esophagus[e](#tfn6-co16-4-48){ref-type="table-fn"} \[*n* (%)\]                 1 (7)                            0        0   0   0        2 (13)   0   0
  Constitutional symptoms[f](#tfn7-co16-4-48){ref-type="table-fn"} \[*n* (%)\]   3 (20)                           2 (13)   0   0   3 (20)   1 (7)    0   0

According to the U.S. National Cancer Institute Common Toxicity Criteria.

According to Radiation Therapy Oncology Group/European Organization for the Research and Treatment of Cancer late radiation morbidity scoring.

Pneumonitis, cough.

Nausea, diarrhea.

Esophagitis, dysphagia.

Taste alteration, poor appetite, fatigue.

###### 

Pattern of relapse and sites of distal relapse in the study patients

  ------------------------------------------- --------
  *Pattern of first relapse (*N *= 15)*       
  Site \[*n* (%)\]                            
   Anastomotic site only                      0 (0)
   Regional only                              0 (0)
   Distant only                               6 (40)
  *Distal sites of first relapse (*N *= 6)*   
  Organ \[*n* (%)\]                           
   Liver                                      3 (50)
   Lung                                       3 (50)
   Brain                                      2 (33)
   Pleura                                     1 (17)
   Kidney (adrenals)                          1 (17)
   Abdomen                                    1 (17)
   Bone                                       1 (17)
  ------------------------------------------- --------
